Physician profile
Donald Johnson
NPI 1972508422
$1,553.82
in general payments reported to CMS, 2019-2025
15 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.79 · 2022: $578 · 2023: $321 · 2024: $237 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.22 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $197.08 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $192.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $177.72 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $145.18 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Exact Sciences Corporation | $123.85 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $93.10 | 2022-2023 | Dexcom G6 Transmitter |
| Rhythm Pharmaceuticals, INC. | $81.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $66.01 | 2024 | Voquezna |
| Alkermes, INC. | $24.03 | 2023 | Aristada, Lybalvi |
| Abbott Laboratories | $23.47 | 2023 | Freestyle Libre |
| Teva Pharmaceuticals USA, INC. | $20.97 | 2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $20.14 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $18.29 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.